By contrast, the only phase III trial to date, ATHENA-COMBO, did not show benefit for adding nivolumab to PARP inhibitor maintenance in unselected frontline ovarian cancer, and phase II data in largely pMMR or unselected endometrial cancer have been modest, with benefit confined to biomarker-enriched subgroups. This evidence concerns the gene PARP1 and ovarian carcinoma.